GS-9876 (lanraplenib)

SYK-selective kinase inhibitor

oral, completed Ph. I in HV

from optimization of prior candidate

ACS Med. Chem. Lett. Feb. 12, 2020

Gilead Sciences, Seattle, WA

GS-9876 (lanraplenib) (Gilead Sciences oral SYK selective kinase inhibitor clinical candidate)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.